Skip to main content
Top
Published in: The Journal of Behavioral Health Services & Research 3/2017

01-07-2017

Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data

Authors: Traci R. Rieckmann, PhD, Nicholas Gideonse, MD, Amanda Risser, MD, MPH, Jennifer E. DeVoe, MD, Amanda J. Abraham, PhD

Published in: The Journal of Behavioral Health Services & Research | Issue 3/2017

Login to get access

Abstract

Research has examined the safety, efficacy, feasibility, and cost-effectiveness of buprenorphine for the treatment of opioid dependence, but few studies have examined patient and provider experiences, especially in community health centers. Using de-identified electronic health record system (EHRS) data from 70 OCHIN community health centers (n = 1825), this cross-sectional analysis compared the demographics, comorbidities, and service utilization of patients receiving buprenorphine to those not receiving medication-assisted treatment (MAT). Compared to non-MAT patients, buprenorphine patients were younger and less likely to be Hispanic or live in poverty. Buprenorphine patients were less likely to have Medicaid insurance coverage, more likely to self-pay, and have private insurance coverage. Buprenorphine patients were less likely to have problem medical comorbidities or be coprescribed high-risk medications. It is important for providers, clinic administrators, and patients to understand the clinical application of medications for opioid dependence to ensure safe and effective care within safety net clinics.
Literature
1.
go back to reference Center for Disease Control. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at http://wonder.cdc.gov . Center for Disease Control. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at http://wonder.cdc.gov .
2.
go back to reference Substance Abuse and Mental Health Services Association. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. (HHS Publication No. SMA 15–4927, NSDUH Series H-50), Rockville, MD, 2014. Substance Abuse and Mental Health Services Association. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. (HHS Publication No. SMA 15–4927, NSDUH Series H-50), Rockville, MD, 2014.
4.
go back to reference Shortell SM, Casalino LP, Fisher ES. How the center for Medicare and Medicaid innovation should test accountable care organizations. Health Aff 2010;29(7): 1293–8.CrossRef Shortell SM, Casalino LP, Fisher ES. How the center for Medicare and Medicaid innovation should test accountable care organizations. Health Aff 2010;29(7): 1293–8.CrossRef
5.
go back to reference Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA clinical trials network field experience. Am J Addict 2004;13 Suppl 1:S42–66.CrossRefPubMedPubMedCentral Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA clinical trials network field experience. Am J Addict 2004;13 Suppl 1:S42–66.CrossRefPubMedPubMedCentral
6.
go back to reference Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiatr 1999 Nov;156(11):1758–64.PubMed Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiatr 1999 Nov;156(11):1758–64.PubMed
7.
go back to reference Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: What to expect. Fam Med 2008;40(7):500–6.PubMedPubMedCentral Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: What to expect. Fam Med 2008;40(7):500–6.PubMedPubMedCentral
8.
go back to reference Fiellin DA, Pantalon MV, Pakes JP, et al. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2): 231–41.CrossRefPubMed Fiellin DA, Pantalon MV, Pakes JP, et al. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2): 231–41.CrossRefPubMed
9.
go back to reference Johnson R, Chutuape M, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343(18): 1290–7.CrossRefPubMed Johnson R, Chutuape M, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343(18): 1290–7.CrossRefPubMed
10.
go back to reference Ling W, Charuvastra C, Collins J, et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998;93(4): 475–86.CrossRefPubMed Ling W, Charuvastra C, Collins J, et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998;93(4): 475–86.CrossRefPubMed
11.
go back to reference Monti P, Rohsenow D, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25(11): 1634–47.CrossRefPubMed Monti P, Rohsenow D, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25(11): 1634–47.CrossRefPubMed
13.
go back to reference Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. Arch Gen Psychiatry 2011;68(12): 1238–46.CrossRefPubMedPubMedCentral Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. Arch Gen Psychiatry 2011;68(12): 1238–46.CrossRefPubMedPubMedCentral
14.
go back to reference Comer SD, Walker EA, Collins ED. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 2005;181(4): 664–75.CrossRefPubMedPubMedCentral Comer SD, Walker EA, Collins ED. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 2005;181(4): 664–75.CrossRefPubMedPubMedCentral
15.
go back to reference Ducharme S, Fraser R, Gill K. Update on the clinical use of buprenorphine in opioid-related disorders. Can Fam Physician 2012;58(1):37–41.PubMedPubMedCentral Ducharme S, Fraser R, Gill K. Update on the clinical use of buprenorphine in opioid-related disorders. Can Fam Physician 2012;58(1):37–41.PubMedPubMedCentral
16.
go back to reference Ling W, Jacobs P, Hillhouse M, et al. From research to real world: Buprenorphine in the decade of the Clinical Trials Network. J Subst Abus Treat 2010;38(S1): S53–60.CrossRef Ling W, Jacobs P, Hillhouse M, et al. From research to real world: Buprenorphine in the decade of the Clinical Trials Network. J Subst Abus Treat 2010;38(S1): S53–60.CrossRef
17.
go back to reference Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis 2006;43(S4): S173–7.CrossRefPubMed Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis 2006;43(S4): S173–7.CrossRefPubMed
18.
go back to reference Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician 2011;57(3): 281–9.PubMedPubMedCentral Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician 2011;57(3): 281–9.PubMedPubMedCentral
19.
go back to reference Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs 2010 Sep;42(3):339–46.CrossRefPubMedPubMedCentral Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs 2010 Sep;42(3):339–46.CrossRefPubMedPubMedCentral
20.
go back to reference Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abus Treat 2010;39(4): 340–52.CrossRef Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abus Treat 2010;39(4): 340–52.CrossRef
21.
go back to reference Ridge G, Gossop M, Lintzeris N. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abus Treat 2009;37(1): 95–100.CrossRef Ridge G, Gossop M, Lintzeris N. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abus Treat 2009;37(1): 95–100.CrossRef
22.
go back to reference Polsky D, Glick HA, Yang J, et al. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction 2010;105(9): 1616–24.CrossRefPubMedPubMedCentral Polsky D, Glick HA, Yang J, et al. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction 2010;105(9): 1616–24.CrossRefPubMedPubMedCentral
23.
go back to reference American Society of Addiction Medicine. 2016 The National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD American Society of Addiction Medicine. 2016 The National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MD
24.
go back to reference Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP). Series 40, DHHS Publication No. (SMA) 04–3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP). Series 40, DHHS Publication No. (SMA) 04–3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.
25.
go back to reference Centers for Disease Control and Prevention. Planning and Implementing Screening and Brief Intervention for Risky Alcohol Use: A Step-by-Step Guide for Primary Care Practices. Atlanta, Georgia: Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, 2014. Centers for Disease Control and Prevention. Planning and Implementing Screening and Brief Intervention for Risky Alcohol Use: A Step-by-Step Guide for Primary Care Practices. Atlanta, Georgia: Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, 2014.
26.
go back to reference Baldini A, Von Korff M, Lin EH. 2012 A review of potential adverse effects of long-term opioid therapy: a practitioner’s guide. The Primary Care Companion for CNS Disorders. 14(3) Baldini A, Von Korff M, Lin EH. 2012 A review of potential adverse effects of long-term opioid therapy: a practitioner’s guide. The Primary Care Companion for CNS Disorders. 14(3)
27.
go back to reference Costenbader EC, Zule WA, Coomes CM. The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for Hepatitis C infection. Drug Alcohol Depend 2007;89(2–3): 251–58.CrossRefPubMedPubMedCentral Costenbader EC, Zule WA, Coomes CM. The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for Hepatitis C infection. Drug Alcohol Depend 2007;89(2–3): 251–58.CrossRefPubMedPubMedCentral
29.
go back to reference Howard AA, Hoover DR, Anastos K, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the women’s interagency HIV study. J Acquir Immune Defic Syndr 2010;54(2): 152–59.PubMedPubMedCentral Howard AA, Hoover DR, Anastos K, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the women’s interagency HIV study. J Acquir Immune Defic Syndr 2010;54(2): 152–59.PubMedPubMedCentral
31.
go back to reference Rowe TA, Jacapraro JS, Rastegar DA. Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems. Addiction Science and Clinical Practice 2012;7(22): 1–5. Rowe TA, Jacapraro JS, Rastegar DA. Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems. Addiction Science and Clinical Practice 2012;7(22): 1–5.
33.
go back to reference Grella CE, Karno MP, Warda US, et al. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav 2009;34(6–7): 498–504.CrossRefPubMedPubMedCentral Grella CE, Karno MP, Warda US, et al. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav 2009;34(6–7): 498–504.CrossRefPubMedPubMedCentral
34.
go back to reference Bogdanowicz KM, Stewart R, Broadbent M, et al. Double trouble: Psychiatric comorbidity and opioid addiction-all-cause and cause-specific mortality. Drug Alcohol Depend 2015; 148: 85–92.CrossRefPubMed Bogdanowicz KM, Stewart R, Broadbent M, et al. Double trouble: Psychiatric comorbidity and opioid addiction-all-cause and cause-specific mortality. Drug Alcohol Depend 2015; 148: 85–92.CrossRefPubMed
35.
go back to reference Mannelli P, Wu L-T, Peindl KS, Gorelick DA. Smoking and Opioid Detoxification: Behavioral Changes and Response to Treatment. Nicotine Tob Res 2013;15(10):1705–1713.CrossRefPubMedPubMedCentral Mannelli P, Wu L-T, Peindl KS, Gorelick DA. Smoking and Opioid Detoxification: Behavioral Changes and Response to Treatment. Nicotine Tob Res 2013;15(10):1705–1713.CrossRefPubMedPubMedCentral
36.
go back to reference Saunders SA, Democratis J, Martin J, et al. Intravenous drug abuse and type 1 diabetes: Financial and healthcare implications. Diabet Med 2004;21(12): 1269–73.CrossRefPubMed Saunders SA, Democratis J, Martin J, et al. Intravenous drug abuse and type 1 diabetes: Financial and healthcare implications. Diabet Med 2004;21(12): 1269–73.CrossRefPubMed
37.
go back to reference Stein MD. Medical consequences of substance abuse. The Psychiatry Clinics of North America 1999;22(2): 351–70.CrossRef Stein MD. Medical consequences of substance abuse. The Psychiatry Clinics of North America 1999;22(2): 351–70.CrossRef
38.
40.
go back to reference McCance-Katz EF, Sullivan L, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict 2010;19(1): 4–16.CrossRefPubMedPubMedCentral McCance-Katz EF, Sullivan L, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict 2010;19(1): 4–16.CrossRefPubMedPubMedCentral
41.
go back to reference McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007;91(2–3): 269–78.CrossRefPubMedPubMedCentral McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007;91(2–3): 269–78.CrossRefPubMedPubMedCentral
42.
go back to reference Tai B, McLellan AT. Integrating information on substance use disorders into electronic health record systems. J Subst Abus Treat 2012;43(1): 12–9.CrossRef Tai B, McLellan AT. Integrating information on substance use disorders into electronic health record systems. J Subst Abus Treat 2012;43(1): 12–9.CrossRef
43.
go back to reference Fiellin DA, O’Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002;137(8): 688–92.CrossRefPubMed Fiellin DA, O’Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002;137(8): 688–92.CrossRefPubMed
44.
go back to reference Mintzer IL, Eisenberg M, Terra M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007;5(2): 146–50.CrossRefPubMedPubMedCentral Mintzer IL, Eisenberg M, Terra M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007;5(2): 146–50.CrossRefPubMedPubMedCentral
45.
go back to reference Substance Abuse and Mental Health Services Administration. Alcohol and Drug Services Study (ADSS). The National Treatment System: Outpatient Methadone Facilities. Rockville, MD: Office of Applied Studies, 2004. Substance Abuse and Mental Health Services Administration. Alcohol and Drug Services Study (ADSS). The National Treatment System: Outpatient Methadone Facilities. Rockville, MD: Office of Applied Studies, 2004.
46.
go back to reference Shah S, Diwan S. Methadone: Does stigma play a role as a barrier to treatment of chronic pain? Pain Physician 2010;13(3): 289–93.PubMed Shah S, Diwan S. Methadone: Does stigma play a role as a barrier to treatment of chronic pain? Pain Physician 2010;13(3): 289–93.PubMed
47.
go back to reference Cunningham C, Sohler NL, McCoy K, et al. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med 2006;38(5): 336–40.PubMed Cunningham C, Sohler NL, McCoy K, et al. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med 2006;38(5): 336–40.PubMed
48.
go back to reference Felice AM, Kouimtsidis C. Improving services offered by GPs to patients with drug addiction. Ment Health Pract 2012;16(1):19–22.CrossRef Felice AM, Kouimtsidis C. Improving services offered by GPs to patients with drug addiction. Ment Health Pract 2012;16(1):19–22.CrossRef
49.
go back to reference Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2014. Data on Substance Abuse Treatment Facilities. BHSIS Series S-79, HHS Publication No. (SMA) 16-4963. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2014. Data on Substance Abuse Treatment Facilities. BHSIS Series S-79, HHS Publication No. (SMA) 16-4963. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.
50.
go back to reference Substance Abuse and Mental Health Services Administration. The determinations report: a report on the physician waiver program established by the drug addiction treatment act of 2000 (“DATA”). Rockville, MD: U.S. Department of Health and Human Services, 2006. Substance Abuse and Mental Health Services Administration. The determinations report: a report on the physician waiver program established by the drug addiction treatment act of 2000 (“DATA”). Rockville, MD: U.S. Department of Health and Human Services, 2006.
51.
go back to reference Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abus Treat 2009;36(3): 244–51.CrossRef Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abus Treat 2009;36(3): 244–51.CrossRef
53.
go back to reference Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville, MD: Substance Abuse and Mental Health Administration, 2005. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville, MD: Substance Abuse and Mental Health Administration, 2005.
54.
go back to reference Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis 2006;25(4): 91–103.CrossRefPubMed Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis 2006;25(4): 91–103.CrossRefPubMed
55.
go back to reference Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug Alcohol Depend 2007;87(2–3): 164–74.CrossRefPubMed Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug Alcohol Depend 2007;87(2–3): 164–74.CrossRefPubMed
56.
go back to reference Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication assisted treatment. Am J Public Health 2015;105(8): 55–63.CrossRef Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication assisted treatment. Am J Public Health 2015;105(8): 55–63.CrossRef
57.
go back to reference Clark RE, Samnaliev M, Baxter JD, et al. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff 2011;30(8): 1425–33.CrossRef Clark RE, Samnaliev M, Baxter JD, et al. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff 2011;30(8): 1425–33.CrossRef
58.
go back to reference StataCorp. Release 13: Statistical software [computer program]. College Station, TX: StataCorp LP, 2013. StataCorp. Release 13: Statistical software [computer program]. College Station, TX: StataCorp LP, 2013.
59.
go back to reference Sullivan L, Chawarski M, O'Connor P, et al. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug Alcohol Depend 2005;79(1): 113–6.CrossRefPubMed Sullivan L, Chawarski M, O'Connor P, et al. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug Alcohol Depend 2005;79(1): 113–6.CrossRefPubMed
62.
64.
go back to reference Duncan LG, Mendoza S, Hansen H. Buprenorphine maintenance for opioid dependence in public sector healthcare: Benefits and barriers. Journal of Addiction Medicine and Therapeutic Science 2015;1(2):31–36.CrossRefPubMedPubMedCentral Duncan LG, Mendoza S, Hansen H. Buprenorphine maintenance for opioid dependence in public sector healthcare: Benefits and barriers. Journal of Addiction Medicine and Therapeutic Science 2015;1(2):31–36.CrossRefPubMedPubMedCentral
65.
go back to reference DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA Jr. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health 2015;15:3019.PubMed DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA Jr. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health 2015;15:3019.PubMed
67.
go back to reference Druss BG, Von Esenwein SA. Improving general medical care for persons with mental and addictive disorders: Systematic review. Gen Hosp Psychiatry 2006;28(2): 145–53.CrossRefPubMed Druss BG, Von Esenwein SA. Improving general medical care for persons with mental and addictive disorders: Systematic review. Gen Hosp Psychiatry 2006;28(2): 145–53.CrossRefPubMed
Metadata
Title
Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data
Authors
Traci R. Rieckmann, PhD
Nicholas Gideonse, MD
Amanda Risser, MD, MPH
Jennifer E. DeVoe, MD
Amanda J. Abraham, PhD
Publication date
01-07-2017
Publisher
Springer US
Published in
The Journal of Behavioral Health Services & Research / Issue 3/2017
Print ISSN: 1094-3412
Electronic ISSN: 2168-6793
DOI
https://doi.org/10.1007/s11414-017-9553-z

Other articles of this Issue 3/2017

The Journal of Behavioral Health Services & Research 3/2017 Go to the issue